Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations

NCT01171313 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

NCT NCT01171313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01171313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations
Lead sponsor
XenoPort, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
December 31, 2011
Enrollment
35 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease